CDKN2B-AS1
CDKN2B-AS1rnaCDKN2B-AS1 is a 9p21 locus CAD-risk lncRNA that epigenetically controls smooth-muscle-cell function and atherosclerotic inflammation.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleCAD susceptibility locus; long noncoding RNA regulating SMC splicing and plaque inflammation; MI risk gene.
Also acts inCap degradation / rupture
Druggability
DruggableNo
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableNo
EnsemblENSG00000240498
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood (transcript)
Collection tube
PAXgene/Tempus RNA tube · K2/K3-EDTA (lavender-top)
Method / principle
RT-qPCR (TaqMan) or small-RNA sequencing
Reagent / substrate
Target-specific primers/probe; reverse transcriptase (miRNA: stem-loop RT primer)
Platform
qPCR instrument / NGS
Turnaround · availability
Research / send-out · Research (few LDTs)
Human genetic evidence
18
GWAS associations
Traits: myocardial infarction
Literature evidence(4)
- Genetic Regulation of SMC Gene Expression and Splicing Predict Causal CAD Genes.Circulation research · 2023 · PMID 36597873 · doi
- Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus.Cardiovascular research · 2021 · PMID 32077919 · doi
- Association of six genetic variants with myocardial infarction.International journal of molecular medicine · 2015 · PMID 25738804 · doi
- From genotype to phenotype in human atherosclerosis--recent findings.Current opinion in lipidology · 2013 · PMID 24005217 · doi